- TV Footage
- Integrated Annual Reports
- Quarterly Reports
- Bayer Magazine
- BEENOW Magazine
- Farming’s Future Magazine
- research Magazine
- technology solutions Magazine
- From Molecules to Medicine
- From Molecules to Veterinary Medicines Brochure
- Integrated Weed Management
- Names | Figures | Facts
- Transfers of Value to Physicians Brochure
- Newsletter Overview
- Social Media
- Media Contact
Geneva, May 12, 2016 – Ensuring vitamin and mineral levels in healthy, normal populations can provide significant beneficial effects in terms of cognitive performance and brain function, according to study findings presented by Professor Dr. David Kennedy and Professor Dr. Andrew Scholey at the Vitafoods Europe 2016 Conference. Kennedy, the Director of the Brain, Performance and Nutrition Research Centre in the School of Life Science at Northumbria University in Newcastle, UK, concluded that supplementation with B vitamins as are contained in Berocca™ Performance from Bayer significantly improves general mental health, reduces subjective stress and increases vigor and overall mood. Scholey, Director of the Centre for Human Psychopharmacology at Swinburne University, Australia, presented new data indicating that Berocca™ Performance supplementation increased activation in brain regions associated with attention and working memory. The conference was held on the occasion of the Vitafoods nutraceutical event at Palexpo, Geneva, Switzerland from May 10 to 12, 2016.
In his studies, Professor Kennedy has taken a closer look at the inter-related functions of the eight B vitamins and marshals evidence suggesting that adequate levels of all members of this group of micronutrients are essential for optimal physiological and neurological functioning.(1) His findings have demonstrated significant benefits to brain function following four weeks of Berocca™ Performance supplementation in healthy individuals.(2,3)
In his review, Kennedy concludes that in absence of an optimal diet, administration of the entire vitamin-B group rather than a small sub-set, at doses in excess of the current governmental recommendation, would be a rational approach for supporting brain function. His studies also show that Berocca™ Performance improved cognitive performance during intense mental processing and reduced associated mental tiredness.
Dr. Silvia Maggini, Director of Global Medical Affairs Nutritionals at the Consumer Health Division of Bayer in Basel, Switzerland, said: “A deficiency of one or more B vitamins, vitamin C, as well as calcium, magnesium, and zinc, often results in reduced tolerance in stressful situations in everyday life. This can lead to symptoms such as irritability, anxiety, inhability to concentrate, and fatigue.”
Additional research presented at the conference highlighted the effect of micronutrient supplementation on brain function. Professor Scholey spoke about the results of a four-week assessment on neurotropic multi-vitamins supplementation. Scholey’s study findings confirmed that supplementation of neurotropic multi-vitamins, such as Berocca™ Performance from Bayer, is associated with improvements in mood(4) and functional brain activity(5). With his team he mapped brain activity using two state of the art technologies: Steady State Topography and functional magnetic resonance imaging (fMRI) which detects blood flow changes in the brain. Both technologies showed increased activation in parietal-frontal brain regions associated with attention and working memory in healthy young adults.
Supplemental multi-vitamins like Berocca™ Performance, which is a unique formula that contains high doses of the water-soluble B complex vitamins, vitamin C, calcium, magnesium and zinc, help counteract an inadequate intake of vitamins and minerals, thereby supporting physical and mental well being. “The results of our recent scientific trial add to the available evidence for Berocca™ Performance and confirm that multi-vitamin supplementation in healthy adults can support mental performance and mood,” said Scholey.
(1) Kennedy D.O. B Vitamins and the Brain: Mechanisms, Dose and Efficacy-A Review. Nutrients. 2016 Jan 27;8(2). pii: E68. doi: 10.3390/nu8020068.
(2) Kennedy, D.O. Effects of high-dose B vitamin complex with vitamin C and minerals on subjective mood and performance in healthy males. Psychopharmacology (Berl). 2010 Jul;211(1):55-68.
(3) Kennedy, D.O. Vitamins and psychological functioning: a mobile pone assessment oft he effects of a B vitamin complex, vitamin C and minerals on cognitive performance and subjective mood and energy. Hum Psychopharmacol. 2011 Jun-Jul;26(4-5):338-47.
(4) White DJ, Cox KH, Peters R, Pipingas A, Scholey AB. Effects of Four-Week Supplementation with a Multi-Vitamin/Mineral Preparation on Mood and Blood Biomarkers in Young Adults: A Randomised, Double-Blind, Placebo-Controlled Trial. Nutrients. 2015 Oct 30;7(11):9005-17. doi: 10.3390/nu7115451.
(5) White DJ, Scholey AB et al, 2015 Effects of 4 weeks supplementation with a multivitamin and mineral preparation on mood and functional brain activity (344) Joint Annual Scientific Meeting of the Nutrition Association of New Zealand and the Nutrition Association of Australia.
Bayer: Science For A Better Life
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Bayer is committed to the principles of sustainable development and to its social and ethical responsibilities as a corporate citizen. In fiscal 2015, the Group employed around 117,000 people and had sales of EUR 46.3 billion. Capital expenditures amounted to EUR 2.6 billion, R&D expenses to EUR 4.3 billion. These figures include those for the high-tech polymers business, which was floated on the stock market as an independent company named Covestro on October 6, 2015. For more information, go to www.bayer.com.
Find more information at www.bayer.com.
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.